BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Dong XW, Zheng Q, Zhu MM, Tong JL, Ran ZH. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol 2010; 16(25): 3187-3195 [PMID: 20593505 DOI: 10.3748/wjg.v16.i25.3187]
URL: https://www.wjgnet.com/1007-9327/full/v16/i25/3187.htm
Number Citing Articles
1
L. Beaugerie. Commentary: monitoring for myelosuppression in IBDAlimentary Pharmacology & Therapeutics 2013; 37(1): 154 doi: 10.1111/apt.12108
2
Mahmoud H Mosli, William J Sandborn, Richard B Kim, Reena Khanna, Bandar Al-Judaibi, Brian G Feagan. Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology 2014; 109(7): 994 doi: 10.1038/ajg.2014.110
3
Richard Myles Turner, Munir Pirmohamed. Preventive and Predictive Genetics: Towards Personalised MedicineAdvances in Predictive, Preventive and Personalised Medicine 2015; 9: 109 doi: 10.1007/978-3-319-15344-5_6
4
Geoffrey C. Wall, Hamid Muktar, Cassandra Effken, Pramod B. Mahajan. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2018; 38(2): 259 doi: 10.1002/phar.2067
5
Simran D. S. Maggo, Ruth L. Savage, Martin A. Kennedy. Impact of New Genomic Technologies on Understanding Adverse Drug ReactionsClinical Pharmacokinetics 2016; 55(4): 419 doi: 10.1007/s40262-015-0324-9
6
Marta Gutiérrez-Valencia, Leire Leache, Luis Carlos Saiz, Juan J. Beloqui, Miguel Barajas, Miren Vicuña, Juan Erviti. Role of Pharmacogenomics in the Efficacy and Safety of Thiopurines in Inflammatory Bowel DiseaseJournal of Clinical Gastroenterology 2023; 57(7): 671 doi: 10.1097/MCG.0000000000001791
7
Vishakha Tambe, Bhagwat Sirsat, Kuldeep Rajpoot, Anuradha Gadeval, Rakesh Kumar Tekade. Biopharmaceutics and Pharmacokinetics Considerations2021; : 355 doi: 10.1016/B978-0-12-814425-1.00021-8
8
Choon Jin Ooi, Govind K Makharia, Ida Hilmi, Peter R Gibson, Kwong Ming Fock, Vineet Ahuja, Khoon Lin Ling, Wee Chian Lim, Kelvin T Thia, Shu‐chen Wei, Wai Keung Leung, Poh Koon Koh, Richard B Gearry, Khean Lee Goh, Qin Ouyang, Jose Sollano, Sathaporn Manatsathit, H Janaka de Silva, Rungsun Rerknimitr, Pises Pisespongsa, Muhamad Radzi Abu Hassan, Joseph Sung, Toshifumi Hibi, Christopher C M Boey, Neil Moran, Rupert W L Leong. Asia–Pacific consensus statements on Crohn's disease. Part 2: ManagementJournal of Gastroenterology and Hepatology 2016; 31(1): 56 doi: 10.1111/jgh.12958
9
Marieke J.H. Coenen, Dirk J. de Jong, Corine J. van Marrewijk, Luc J.J. Derijks, Sita H. Vermeulen, Dennis R. Wong, Olaf H. Klungel, Andre L.M. Verbeek, Piet M. Hooymans, Wilbert H.M. Peters, Rene H.M. te Morsche, William G. Newman, Hans Scheffer, Henk-Jan Guchelaar, Barbara Franke, A.A.M. Masclee, M. Pierik, W. Mares, W. Hameeteman, P.J. Wahab, H. Seinen, M.C.M. Rijk, I.M. Harkema, M. de Bièvre, L. Oostenbrug, C.M. Bakker, M. Aquarius, C. van Deursen, A.B. van Nunen, J.G. Goedhard, M. Hamacher, I.A.M. Gisbertz, B.J. Brenninkmeijer, A.C.I.T.L. Tan, M.N. Aparicio-Pagés, E.M. Witteman, S.A.C. van Tuyl, R. Breumelhof, A. Stronkhorst, L.P.L. Gilissen, E.J. Schoon, J.W.M. Tjhie-Wensing, A. Temmerman, J.J. Nicolaï, J.D. van Bergeijk, D.J. Bac, B.J.M. Witteman, N. Mahmmod, J.J. Uil, H. Akol, R.J.T. Ouwendijk, I.P. van Munster, M. Pennings, A.M.P. De Schryver, T.J.M. van Ditzhuijsen, R.C.H. Scheffer, T.E.H. Römkens, D.L. Schipper, P.J. Bus, J.W.A. Straathof, M.L. Verhulst, P.J. Boekema, J.T. Kamphuis, H.J. van Wijk, J.M.J.L. Salemans, J.R. Vermeijden, S.D.J. van der Werf, R.J. Verburg, P. Spoelstra, J.M.L. de Vree, K. van der Linde, H.J.A. Jebbink, M. Jansen, H. Holwerda, N. van Bentem, J.J. Kolkman, M.G.V.M. Russel, G.H. van Olffen, M.J. Kerbert-Dreteler, M. Bargeman, J.M. Götz, R. Schröder, J.M. Jansen, L.P. Bos, L.G.J.B. Engels, M.J.L. Romberg-Camps, E.T.P. Keulen, A.A.J. van Esch, J.P.H. Drenth, M.C.A. van Kouwen, G.J.A. Wanten, T.J. Bisseling, T.E.H. Römkens, M.W.J. van Vugt, P.C. van de Meeberg, S.J. van den Hazel, W.N.H.M. Stuifbergen, M.J.A.L. Grubben, U. de Wit, G.A.H. Dodemont, R.F. Eichhorn, J.M.H. van den Brande, A. H.J. Naber, E.J. van Soest, P.J. Kingma, N.C. Talstra, K.F. Bruin, F.H.J. Wolfhagen, D.W. Hommes, P.P.J. van der Veek, J.C.A. Hardwick, R.J. Stuyt, H.H. Fidder, B. Oldenburg, T.G. Tan. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel DiseaseGastroenterology 2015; 149(4): 907 doi: 10.1053/j.gastro.2015.06.002
10
G. V. Volynets, A. I. Khavkin. Inflammatory bowel disease and drug-induced liver damageExperimental and Clinical Gastroenterology 2021; (10): 138 doi: 10.31146/1682-8658-ecg-194-10-138-146
11
Maria Cappello, Gaetano Cristian Morreale. The Role of Laboratory Tests in Crohn's DiseaseClinical Medicine Insights: Gastroenterology 2016; 9: CGast.S38203 doi: 10.4137/CGast.S38203
12
Paria Pashazadeh, Abdoljalal Marjani, Jahanbakhash Asadi, Masoud Khoshnia. Thiopurine Methyltransferase Genetic Polymorphisms and Activity and Metabolic Products of Azathioprine in Patients with Inflammatory Bowel DiseaseEndocrine, Metabolic & Immune Disorders - Drug Targets 2019; 19(4): 541 doi: 10.2174/1871530318666181119153522
13
Ji Young Chang, Jae Hee Cheon. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and PharmacogeneticsDigestive Diseases and Sciences 2019; 64(9): 2395 doi: 10.1007/s10620-019-05720-5
14
Vid Mlakar, Patricia Huezo-Diaz Curtis, Chakradhara Satyanarayana Uppugunduri, Maja Krajinovic, Marc Ansari. Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical UseInternational Journal of Molecular Sciences 2016; 17(9): 1502 doi: 10.3390/ijms17091502
15
Patricia Zerra, John Bergsagel, Frank G. Keller, Glen Lew, Melinda Pauly. Maintenance Treatment With Low‐Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine‐Induced PancreatitisPediatric Blood & Cancer 2016; 63(4): 712 doi: 10.1002/pbc.25841
16
Xando Díaz-Villamarín, Emilio Fernández-Varón, Michelle Carolina Rojas Romero, José Luis Callejas-Rubio, José Cabeza-Barrera, Alba Rodríguez-Nogales, Julio Gálvez, Rocío Morón. Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementationBiomedicine & Pharmacotherapy 2023; 168: 115706 doi: 10.1016/j.biopha.2023.115706
17
Tiziana Larussa, Evelina Suraci, Margherita Lentini, Immacolata Nazionale, Luigia Gallo, Ludovico Abenavoli, Maria Imeneo, Francesco Saverio Costanzo, Giovanni Cuda, Francesco Luzza. High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel diseaseEuropean Journal of Internal Medicine 2012; 23(3): 273 doi: 10.1016/j.ejim.2011.12.002
18
Christian Mottet, Alain M. Schoepfer, Pascal Juillerat, Jacques Cosnes, Florian Froehlich, Vera Kessler-Brondolo, Frank Seibold, Gerhard Rogler, Stephan R. Vavricka, Pierre Michetti. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel DiseaseInflammatory Bowel Diseases 2016; 22(11): 2733 doi: 10.1097/MIB.0000000000000923
19
Lie Li, Natalya Atkinson, Kristine R. Crews, Alejandro R. Molinelli. Clinical Applications of Mass Spectrometry in Drug AnalysisMethods in Molecular Biology 2024; 2737: 443 doi: 10.1007/978-1-0716-3541-4_41
20
Yago González-Lama, Javier P Gisbert. Monitoring thiopurine metabolites in inflammatory bowel diseaseFrontline Gastroenterology 2016; 7(4): 301 doi: 10.1136/flgastro-2015-100681
21
Adriane D.M. Vorselaars, Johanna P. Cremers, Jan C. Grutters, Marjolein Drent. Cytotoxic agents in sarcoidosisCurrent Opinion in Pulmonary Medicine 2014; 20(5): 479 doi: 10.1097/MCP.0000000000000078
22
Olof Modén, Bengt Mannervik. Redox and Cancer Part AAdvances in Cancer Research 2014; 122: 199 doi: 10.1016/B978-0-12-420117-0.00006-2
23
Giuseppe Novelli, Michela Biancolella. Encyclopedia of Life Sciences2011;  doi: 10.1002/9780470015902.a0002012.pub2
24
Jaimin Amin, Brian Huang, Jessica Yoon, David Q. Shih. Update 2014Inflammatory Bowel Diseases 2015; 21(2): 445 doi: 10.1097/MIB.0000000000000197
25
Hilbert S. de Vries, Rene H.M. te Morsche, Kevin Jenniskens, Wilbert H.M. Peters, Dirk J. de Jong. A functional polymorphism in UGT1A1 related to hyperbilirubinemia is associated with a decreased risk for Crohn's diseaseJournal of Crohn's and Colitis 2012; 6(5): 597 doi: 10.1016/j.crohns.2011.11.010
26
Birendra P. Sah, Shraddha Goyal, Michael C. Iannuzzi. Novel pharmacotherapy of sarcoidosisPharmacology & Therapeutics 2016; 157: 1 doi: 10.1016/j.pharmthera.2015.10.001
27
Ben Warner, Emma Johnston, Monica Arenas-Hernandez, Anthony Marinaki, Peter Irving, Jeremy Sanderson. A practical guide to thiopurine prescribing and monitoring in IBDFrontline Gastroenterology 2018; 9(1): 10 doi: 10.1136/flgastro-2016-100738
28
Michele S. Barnhill, Joshua M. Steinberg, Joseph J. Jennings, James H. Lewis. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 UpdateCurrent Gastroenterology Reports 2020; 22(9) doi: 10.1007/s11894-020-00781-3
29
Arvind I. Srinath, Neera Gupta, Sohail Z. Husain. Probing the Association of Pancreatitis in Inflammatory Bowel DiseaseInflammatory Bowel Diseases 2016; 22(2): 465 doi: 10.1097/MIB.0000000000000611
30
Nathalie K. Zgheib, Thalia Arawi, Rami A. Mahfouz, Ramzi Sabra. Attitudes of Health Care Professionals Toward Pharmacogenetic TestingMolecular Diagnosis & Therapy 2011; 15(2): 115 doi: 10.1007/BF03256401
31
Jasmine A Luzum, Jason C Cheung. Does Cardiology Hold Pharmacogenetics to an Inconsistent Standard? A Comparison of Evidence Among RecommendationsPharmacogenomics 2018; 19(15): 1203 doi: 10.2217/pgs-2018-0097
32
Raphael P. Luber, Sailish Honap, Georgina Cunningham, Peter M. Irving. Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?Frontiers in Medicine 2019; 6 doi: 10.3389/fmed.2019.00279
33
Amine Benmassaoud, Xuanqian Xie, Motaz AlYafi, Yves Theoret, Alain Bitton, Waqqas Afif, Talat Bessissow. Thiopurines in the Management of Crohn’s Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity—A Retrospective StudyCanadian Journal of Gastroenterology and Hepatology 2016; 2016: 1 doi: 10.1155/2016/1034834
34
Yue-Ping Liu, Hai-Yan Wu, Xiang Yang, Han-Qing Xu, Yong-Chuan Li, Da-Chuan Shi, Jun-Fu Huang, Qing Huang, Wei-Ling Fu, Yi-Hsiang Hsu. Association between Thiopurine S-methyltransferase Polymorphisms and Thiopurine-Induced Adverse Drug Reactions in Patients with Inflammatory Bowel Disease: A Meta-AnalysisPLOS ONE 2015; 10(3): e0121745 doi: 10.1371/journal.pone.0121745
35
Adriane D.M. Vorselaars, Wim A. Wuyts, Veronique M.M. Vorselaars, Pieter Zanen, Vera H.M. Deneer, Marcel Veltkamp, Michiel Thomeer, Coline H.M. van Moorsel, Jan C. Grutters. Methotrexate vs Azathioprine in Second-line Therapy of SarcoidosisChest 2013; 144(3): 805 doi: 10.1378/chest.12-1728
36
Arno C. Hessels, Abraham Rutgers, Jan Stephan F. Sanders, Coen A. Stegeman, Marieke J. H. Coenen. Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody associated vasculitis: A retrospective cohort studyPLOS ONE 2018; 13(4): e0195524 doi: 10.1371/journal.pone.0195524
37
Adrian Reuben. Drug-Induced Liver Disease2013; : 569 doi: 10.1016/B978-0-12-387817-5.00031-5
38
Gerhard Rogler, Luc Biedermann. Clinical Utility of Biomarkers in IBDCurrent Gastroenterology Reports 2015; 17(7) doi: 10.1007/s11894-015-0449-x
39
Heh-Shiang Sheu, Yi-Ming Chen, Yi-Ju Liao, Chia-Yi Wei, Jun-Peng Chen, Hsueh-Ju Lin, Wei-Ting Hung, Wen-Nan Huang, Yi-Hsing Chen. Thiopurine S-Methyltransferase Polymorphisms Predict Hepatotoxicity in Azathioprine-Treated Patients with Autoimmune DiseasesJournal of Personalized Medicine 2022; 12(9): 1399 doi: 10.3390/jpm12091399
40
Yue-Ping Liu, Han-Qing Xu, Ming Li, Xiang Yang, Shu Yu, Wei-Ling Fu, Qing Huang, Margaret M DeAngelis. Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-AnalysisPLOS ONE 2015; 10(12): e0144234 doi: 10.1371/journal.pone.0144234
41
Paulina Núñez F, Rodrigo Quera, Constanza Bay, Fabiola Castro, Gabriel Mezzano. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel DiseaseJournal of Crohn's and Colitis 2022; 16(7): 1168 doi: 10.1093/ecco-jcc/jjac013
42
Rohan V Yewale, Balakrishnan S Ramakrishna, Babu Vinish Doraisamy, Pandurangan Basumani, Jayanthi Venkataraman, Kayalvizhi Jayaraman, Ananthavadivelu Murali, Karunakaran Premkumar, Akkim Sathish Kumar. Long‐term safety and effectiveness of azathioprine in the management of inflammatory bowel disease: A real‐world experienceJGH Open 2023; 7(9): 599 doi: 10.1002/jgh3.12955
43
Maria Shipkova, Jutta Franz, Manabu Abe, Corinne Klett, Eberhard Wieland, Tilo Andus. Association Between Adverse Effects Under Azathioprine Therapy and Inosine Triphosphate Pyrophosphatase Activity in Patients With Chronic Inflammatory Bowel DiseaseTherapeutic Drug Monitoring 2011; 33(3): 321 doi: 10.1097/FTD.0b013e31821a7c34
44
Giuseppe Losurdo, Irene Vita Brescia, Chiara Lillo, Martino Mezzapesa, Michele Barone, Mariabeatrice Principi, Enzo Ierardi, Alfredo Di Leo, Maria Rendina. Liver involvement in inflammatory bowel disease: What should the clinician know?World Journal of Hepatology 2021; 13(11): 1534-1551 doi: 10.4254/wjh.v13.i11.1534